Covid-19 roundup: Top an­a­lyst: Re­gen­eron EUA like­ly this week — un­less Trump takes a turn for worse; UK says less than half of res­i­dents will be vac­ci­nat­ed

With Re­gen­eron’s Covid-19 an­ti­body cock­tail be­ing used to treat the high­est-pro­file pa­tient on the plan­et, one top an­a­lyst ex­pects an EUA could be on the hori­zon.

SVB Leerink’s Ge­of­frey Porges sent a note to in­vestors ear­ly Mon­day morn­ing at­tempt­ing to parse through what the use of REGN-CoV2 to al­le­vi­ate Pres­i­dent Don­ald Trump’s symp­toms means for the com­pa­ny. Giv­en that the ther­a­py was used at all, Porges es­ti­mates that the FDA was al­ready re­view­ing its EUA ap­pli­ca­tion and that the au­tho­riza­tion could come “in a mat­ter of days.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.